4Creipp PR, Lust IA, O' Fallon Mu, et al. Plasmal cell Labelling index and betd 2-microglobulin predict surinual independent of thymidine ki- naseand C-reactive protein in multiple myeloma. Blood,1993,81:3382- 3387.
6Stabler A, Baur A, Bast IR, et al. Contrast enhancement and quantitative signal analysis in MR imaging of multiple mydoma: assessment of focal and diffuse growth pattems in marrow correlated with biopsies and survival rates[ J]. AJR, 1996,167:1029 - 1036.
7Palumho A, Beringhen S,Caravita T, et al. Oral melphalan and prednidong chemotherapy plus halidomide compared with melphalan and prednisong along in elderly patients with myeloma: rondomissed conrolled trial [J] Lancet, 2006,367 (9513 ) : 825-381.
8Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma[J]. N Engl J Med, 2003,348(26):2609-2617.
9HideshJma T, Cbauban D, Hayashi T, et al. Proteasome inhibitor PS 341 abrogates IL-6 triggered signaling cascades via easpasede-pendentd Ownregulation of gpl 30 in multiple myelorna[J]. Oneogene,2003,22(52) :8386 8393.
